Q-omics provides the consensus-scored REXO1L8P profile across patient tissues and cancer cell-line models. REXO1L8P expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, REXO1L8P is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, REXO1L8P RNA expression shows 5,423 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and HNSC as cancer lineages where REXO1L8P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for REXO1L8P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes REXO1L8P survival associations across molecular data types. REXO1L8P RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible REXO1L8P RNA expression–survival associations across cancer types. High REXO1L8P expression shows unfavorable associations in STAD, LIHC, SKCM, LGG and COAD, but favorable associations in ESCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for REXO1L8P RNA expression.
This table summarizes REXO1L8P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for REXO1L8P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. REXO1L8P shows higher tumor expression in HNSC and STAD. The HNSC box plot shows higher REXO1L8P RNA expression in tumor versus normal tissue (log2 FC = +0.033, t-test p = .026).
This table shows molecular features associated with REXO1L8P in patient tissues and cancer cell lines. In patient samples, REXO1L8P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
